한글목차

표적화 리포좀 약물 전달의 동향과 전망

세계 표적화 리포좀 약물 전달 시장은 2024년부터 2030년까지 8.6%의 연평균 성장률(CAGR)로 2030년까지 약 41억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 암 및 곰팡이 관련 감염을 포함한 만성 질환의 유병률 증가, 체내 약물 대사 및 흡수 과정에 대한 지식과 인식 증가, 새로운 치료 접근법의 채택률 증가입니다. 세계 표적화 리포좀 약물 전달 시장의 미래는 곰팡이 감염 치료와 암 치료 시장에서 기회가 있으며, 유망한 시장으로 평가되고 있습니다.

표적화 리포좀 약물 전달 시장 인사이트

Lucintel의 예측에 따르면, 리포좀 독소루비신은 암 발병률 증가로 인해 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다.

북미는 암 발병률이 높고, 의료 시설이 잘 갖추어져 있어 예측 기간 동안 가장 큰 시장으로 남을 것입니다.

자주 묻는 질문

Q1. 시장 규모는?

A1. 세계 표적화 리포좀 약물 전달 시장은 2030년까지 약 41억 달러에 달할 것으로 예상됩니다.

Q2. 시장 성장 전망은?

A2. 세계 표적화 리포좀 약물 전달 시장은 2024년부터 2030년까지 연평균 8.6%의 성장률을 보일 것으로 예상됩니다.

Q3. 시장 성장에 영향을 미치는 주요 촉진요인은 무엇인가?

A3. 이 시장의 주요 촉진요인은 암 및 곰팡이 관련 감염을 포함한 만성 질환의 발병률 증가, 신체의 약물 대사 및 흡수 과정에 대한 지식과 인식의 향상, 새로운 치료 접근법의 채택률 증가입니다.

Q4. 시장의 주요 부문은?

A4. 세계 표적화 리포좀 약물 전달 시장의 미래는 곰팡이 감염 치료와 암 치료 시장에서 기회가 있고 유망합니다.

Q5. 시장의 주요 기업은?

A5. 주요 표적화 리포좀 약물 전달 기업은 다음과 같습니다.

• Catalent
• Pacira Pharmaceuticals
• Baxter
• Lonza
• Evonik
• Merck
• Fareva
• Vetter
• Polymun Scientific Immunobiologische Forschung
• Recipharm

Q6. 향후 가장 큰 시장 부문은?

A6.Lucintel은 리포좀 독소루비신은 암 발병률 증가로 인해 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상했습니다.

Q7. 향후 5년간 가장 큰 시장으로 성장할 것으로 예상되는 지역은?

A7. 북미는 암 발병률이 높고 의료시설이 잘 갖추어져 있어 예측 기간 동안에도 가장 큰 시장으로 남을 것입니다.

Q8. 보고서 커스터마이징이 가능한가?

A8. 네. Lucintel은 추가 비용없이 10%의 사용자 정의를 제공합니다.

목차

제1장 주요 요약

제2장 세계의 표적화 리포좀 약물 전달 시장 : 시장 역학

• 서론, 배경, 분류
• 공급망
• 업계 촉진요인과 과제

제3장 시장 동향과 예측 분석(2018-2030년)

• 거시경제 동향(2018-2023년)과 예측(2024-2030년)
• 세계의 표적화 리포좀 약물 전달 시장 동향(2018-2023)과 예측(2024-2030)
• 유형별 세계의 표적화 리포좀 약물 전달 시장
  • Liposomal Doxorubicin
  • Liposomal Paclitaxel
  • Liposomal Amphotericin B
  • 기타
• 용도별 세계의 표적화 리포좀 약물 전달 시장
  • 진균 감염증 치료
  • 암 치료
  • 기타

제4장 지역별 시장 동향과 예측 분석(2018-2023년)

• 지역별 세계의 표적화 리포좀 약물 전달 시장
• 북미의 표적화 리포좀 약물 전달 시장
• 유럽의 표적화 리포좀 약물 전달 시장
• 아시아태평양의 표적화 리포좀 약물 전달 시장
• 기타 지역의 표적화 리포좀 약물 전달 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영상 통합
• Porter의 Five Forces 분석

제6장 성장 기회와 전략적 분석

• 성장 기회 분석
  • 유형별 세계의 표적화 리포좀 약물 전달 시장 성장 기회
  • 용도별 세계의 표적화 리포좀 약물 전달 시장 성장 기회
  • 지역별 세계의 표적화 리포좀 약물 전달 시장 성장 기회
• 세계 표적화 리포좀 약물 전달 시장의 새로운 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 표적화 리포좀 약물 전달 시장 능력 확대
  • 세계 표적화 리포좀 약물 전달 시장에서의 인수합병(M&A) 및 합작투자(JV)
  • 인증 및 라이선싱

제7장 유력 기업 개요

• Catalent
• Pacira Pharmaceuticals
• Baxter
• Lonza
• Evonik
• Merck
• Fareva
• Vetter
• Polymun Scientific Immunbiologische Forschung
• Recipharm

영문목차

Targeted Liposomes Drug Delivery Trends and Forecast

The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets. The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

A more than 150-page report is developed to help in your business decisions.

Targeted Liposomes Drug Delivery by Segment

The study includes a forecast for the global targeted liposomes drug delivery by type, application, and region.

Targeted Liposomes Drug Delivery Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Liposomal Doxorubicin
• Liposomal Paclitaxel
• Liposomal Amphotericin B
• Others

Targeted Liposomes Drug Delivery Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Fungal Infection Therapy
• Cancer Therapy
• Others

Targeted Liposomes Drug Delivery Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Targeted Liposomes Drug Delivery Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeted liposomes drug delivery companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeted liposomes drug delivery companies profiled in this report include-

• Catalent
• Pacira Pharmaceuticals
• Baxter
• Lonza
• Evonik
• Merck
• Fareva
• Vetter
• Polymun Scientific Immunbiologische Forschung
• Recipharm

Targeted Liposomes Drug Delivery Market Insights

Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Features of the Global Targeted Liposomes Drug Delivery Market

Market Size Estimates: Targeted liposomes drug delivery market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Targeted liposomes drug delivery market size by type, application, and region in terms of value ($B).

Regional Analysis: Targeted liposomes drug delivery market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeted liposomes drug delivery market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeted liposomes drug delivery market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the targeted liposomes drug delivery market size?

Answer: The global targeted liposomes drug delivery market is expected to reach an estimated $4.1 billion by 2030.

Q2. What is the growth forecast for targeted liposomes drug delivery market?

Answer: The global targeted liposomes drug delivery market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the targeted liposomes drug delivery market?

Answer: The major drivers for this market are rising rates of chronic illnesses including cancer and fungus-related infections, enhanced knowledge and consciousness of the body's medication metabolism and absorption processes, and rising adoption of novel therapeutic approaches.

Q4. What are the major segments for targeted liposomes drug delivery market?

Answer: The future of the global targeted liposomes drug delivery market looks promising with opportunities in the fungal infection therapy and cancer therapy markets.

Q5. Who are the key targeted liposomes drug delivery market companies?

Answer: Some of the key targeted liposomes drug delivery companies are as follows.

• Catalent
• Pacira Pharmaceuticals
• Baxter
• Lonza
• Evonik
• Merck
• Fareva
• Vetter
• Polymun Scientific Immunbiologische Forschung
• Recipharm

Q6. Which targeted liposomes drug delivery market segment will be the largest in future?

Answer: Lucintel forecasts that liposomal doxorubicin is expected to witness highest growth over the forecast period due to the rising incidence rate of cancers.

Q7. In targeted liposomes drug delivery market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to the higher cancer incidence and more sophisticated medical facilities.

Q8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the targeted liposomes drug delivery market by type (liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others), application (fungal infection therapy , cancer therapy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Targeted Liposomes Drug Delivery Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Targeted Liposomes Drug Delivery Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Targeted Liposomes Drug Delivery Market by Type
  • 3.3.1: Liposomal Doxorubicin
  • 3.3.2: Liposomal Paclitaxel
  • 3.3.3: Liposomal Amphotericin B
  • 3.3.4: others
• 3.4: Global Targeted Liposomes Drug Delivery Market by Application
  • 3.4.1: Fungal Infection Therapy
  • 3.4.2: Cancer Therapy
  • 3.4.3: others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Targeted Liposomes Drug Delivery Market by Region
• 4.2: North American Targeted Liposomes Drug Delivery Market
  • 4.2.2: North American Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
• 4.3: European Targeted Liposomes Drug Delivery Market
  • 4.3.1: European Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
  • 4.3.2: European Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
• 4.4: APAC Targeted Liposomes Drug Delivery Market
  • 4.4.1: APAC Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
  • 4.4.2: APAC Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others
• 4.5: ROW Targeted Liposomes Drug Delivery Market
  • 4.5.1: ROW Targeted Liposomes Drug Delivery Market by Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B , and others
  • 4.5.2: ROW Targeted Liposomes Drug Delivery Market by Application: Fungal Infection Therapy , Cancer Therapy, and others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Type
  • 6.1.2: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Application
  • 6.1.3: Growth Opportunities for the Global Targeted Liposomes Drug Delivery Market by Region
• 6.2: Emerging Trends in the Global Targeted Liposomes Drug Delivery Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Targeted Liposomes Drug Delivery Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Targeted Liposomes Drug Delivery Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Catalent
• 7.2: Pacira Pharmaceuticals
• 7.3: Baxter
• 7.4: Lonza
• 7.5: Evonik
• 7.6: Merck
• 7.7: Fareva
• 7.8: Vetter
• 7.9: Polymun Scientific Immunbiologische Forschung
• 7.10: Recipharm